Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + oxaliplatin + leucovorin + fluorouracil
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A multi-drug combination regimen consisting of **nivolumab** (a PD-1 immune checkpoint inhibitor monoclonal antibody), **oxaliplatin** (a platinum-based cytotoxic chemotherapeutic), **leucovorin** (folinic acid, an enhancer of fluorouracil activity), and **fluorouracil** (a fluoropyrimidine antimetabolite), used in the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. Nivolumab enhances antitumor immune response by blocking PD-1 on T cells, oxaliplatin induces DNA crosslinks leading to apoptosis, fluorouracil inhibits thymidylate synthase to disrupt DNA synthesis, and leucovorin potentiates the effect of fluorouracil. The combination is given intravenously, typically every two weeks (mFOLFOX6 protocol), and may confer improved overall survival compared to chemotherapy alone[3][7][9].
- Other names
- nivolumab plus mFOLFOX6nivolumab plus FOLFOXnivolumab combined with fluoropyrimidine- and platinum-containing chemotherapy
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on nivolumab + oxaliplatin + leucovorin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + oxaliplatin + leucovorin + fluorouracil.